Focused Ultrasound Foundation
Total Page：16
File Type：pdf, Size：1020Kb
State of 20the Field 18 Focused Ultrasound Inquiries for reproduction can be directed to Emily White at The Focused Ultrasound Foundation strives to provide the most accurate information possible and, therefore works proactively with the manufactures and research sites to [email protected] collect the most current data available in advance of the release of this publication. The Focused Ultrasound Foundation assumes no responsibility for any errors or omissions as every precaution has been taken to verify the accuracy of the information contained herein. No liability is assumed for damages that may result from the use of information contained within. If you note something out of date or inaccurate, please submit the new Date 9.11.2018 information/updates to: [email protected] 3 Focused Ultrasound Foundation | State of the Field 2018 CONTENTS 2 Focused Ultrasound Overview 44 Commercial Treatment 2 Letter From the Chairman 44 Sites Worldwide 3 Focused Ultrasound Overview 45 Sites by Country 4 State of the Field 46 Indication Master Key 47 Sites by Indication and Region 4 State of Research and Regulatory Approval by Indication 49 North America 6 State of Research and Regulatory Approval by Indication 53 South America and 2017 Global Development Landscape — Oncology 54 Europe 7 2017 Global Development Landscape 67 Africa 10 Developmental Stages of Clinical Indication 67 Oceania 11 Body System Indication Expansion 68 Asia, Except China 12 Expanding Areas of Research by Body System and Indication 74 China 13 Number of Clinical and Preclinical Research Sites 83 Clinical Research by Body Systems 83 Sites Worldwide 14 Patient Treatments 84 Sites by Country 15 Cumulative Patient Treatments by Indication 85 Indication Master Key 16 Cumulative Brain Treatments by Indication 86 Sites by Indication and Region 17 Cumulative Other Treatments by Indication 88 North America 18 Mechanisms of Action 90 South America 19 Research Sites Investigation Mechanisms of Action 91 Europe 20 Technical Research Sites 96 Oceania 21 Abstracts Presented at FUS Symposia 97 Asia 21 FUS Publications 102 Preclinical Research 21 FUS Citations 102 Sites Worldwide 22 Focused Ultrasound Foundation 103 Sites by Country 104 Indication Master Key 22 Activities and Webinar Attendance 105 Sites by Indication and Region 23 Newsletter Distribution 108 All Body Systems Website Visits Symposium Attendance and Presentations 108 North America FUS Media Placements in the US 114 Europe 120 Oceania 24 Sponsorships 122 Asia 25 Invited Talks 126 Oncological 26 Centers of Excellence 126 North America 27 Workshops and Webinars 128 Oceania 28 Veterinary Program 130 Europe 28 Program Sites and Promising Areas of Research 134 Asia 29 Funding 136 Mechanisms of Action Research 136 Sites Worldwide 29 Research Projects Funded by FUSF 137 Sites by Country 29 Total Awards for All FUS NIH Research Grants 138 Sites by Action and Region 30 Manufacturers 140 North America 30 FUS Industry by Region, Clinical Devices Manufacturers 143 Europe 32 FUS Industry by Region, Other FUS Companies 144 Oceania 146 Asia 34 Clinical Device Manufacturers 35 Other Manufacturers 148 Technical Research 36 FUS Regulatory Approval by Indication and Region 148 Sites Worldwide 38 FUS Regulatory Approval by Region and FUS Manufacturer 149 Sites by Country 40 First Global Regulatory Approval for Companies by Indication 150 Sites by Region 43 Contact Information for Commercially Approved Manufacturers 151 North America 43 FUS Partners 152 Europe 153 Asia 155 FUSF Board of Directors and Council Focused Ultrasound Foundation | State of the Field 2018 1 Dear Friends, The past year has brought with it many notable achievements, but one milestone best exemplifies the immense progress in the field. There are now more than 100 clinical indications for which focused ultrasound is in various stages of research, development, and commercialization. Every year there seems to be an astonishing increase from the mere handful that existed when the Foundation was founded in 2006. Counted among those indications are Alzheimer’s disease and pediatric brain tumors, both of which marked their first-in-human treatments this year. Another pioneering trial is the first to combine focused ultrasound and cancer immunotherapy. The Foundation continues to drive growth in the field, thanks to the involvement of our donors, board, and council, and the dedication of our team. We now find that, in such a robust field, our challenge is to maintain focus and devote our finite resources to high-value targets. We are constantly surveying the field to prioritize the mechanisms of action that are most likely to translate into new applications, and the clinical indications that are mostly likely to provide true, unique value. As was the case last year, the 2018 State of the Field includes new charts, graphs, and data summaries. This year we have added sections delineating research sites working with specific mechanisms of action and technical aspects of focused ultrasound. Additionally, there is considerably more content related to the commercialization space—an area of interest if we are to see widespread adoption of this technology. These additions reflect how the field of focused ultrasound has grown and changed over time, further demonstrating its impressive trajectory. In closing, the State of the Field 2018 Report represents progress that is only possible through the hard work, time, and resources of everyone in the field along with collaboration among all stakeholders (this includes donors, researchers, clinicians, the Foundation, etc.) who have become our critical partners in the pursuit of our vision: that focused ultrasound will one day be used to improve the lives of millions of patients around the world suffering from a broad spectrum of serious medical disorders. The revolution continues. Be well, Neal F. Kassell, MD Chairman 2 Focused Ultrasound Foundation | State of the Field 2018 FOCUSED ULTRASOUND OVERVIEW The Technology DRUG DELIVERY Focused ultrasound is an early-stage, noninvasive therapeutic • Focal delivery of therapeutic agents technology with the potential to improve the lives of millions • Increased vascular permeability and blood-brain of patients with a variety of serious medical disorders. It barrier opening offers a disruptive, game-changing alternative or complement • Increased cell membrane permeability to surgery, radiation therapy, drug delivery, and cancer RADIATION immunotherapy. • Alternative to ionizing radiation This revolutionary technology has the potential to increase • Decreased radiation dose: tumor preconditioning the quality and length of life and decrease the cost of care by and sensitization transforming the treatment of such indications as: • benign and malignant tumors of the brain, breast, The Problem prostate, liver, and pancreas It can take decades for a new therapeutic technology like • Parkinson’s and Alzheimer’s disease and epilepsy focused ultrasound to become a mainstream standard of • depression and obsessive-compulsive disorder care. Every year that is subtracted from that process could reduce death, disability, and suffering for countless people. • arthritis and hypertension • uterine fibroids The Focused Ultrasound Foundation Focused ultrasound treats tissue with multiple intersecting The Foundation is a unique medical research, education, and beams of high-frequency sound focused accurately on targets advocacy organization created to accelerate the development deep in the body without damaging surrounding structures, and adoption of focused ultrasound. To achieve its goals, much like beams of light can be focused on a point with the Foundation utilizes an approach that is entrepreneurial, a magnifying glass. At the focal point where the beams high-impact, market-driven, and results-oriented. converge, the ultrasound energy can act in multiple ways to induce a variety of biological effects enabling the treatment Major initiatives include: of a wide variety of medical disorders. Currently there are • Influencing the direction of the field, setting research 18 mechanisms of action including: priorities, and creating an urgent, patient-centric culture TISSUE DESTRUCTION • Providing resources: both human and financial capital • Fostering collaboration and stimulating innovation • Thermal Ablation: coagulative cell death • Histotripsy: mechanical cell disruption • Creating, aggregating, and sharing knowledge • Microvascular disruption: ischemic cell death • Cultivating the next generation of clinicians and scholars • Sonodynamic therapy: activation of cell-toxic drugs • Increasing awareness IMMUNOMODULATION The Foundation has a robust research program and organizes, • Tumor cell disruption: increased immune cell conducts, and supports clinical trials and preclinical laboratory trafficking; exposure of tumor antigens and release studies with an emphasis on brain disorders, cancer, and of cytokines immunotherapy. It is the largest non-governmental source of • Augmentation of immunotherapy drugs focused ultrasound research funding. • Enhanced drug delivery Focused Ultrasound Foundation | State of the Field 2018 3 STATE OF THE FIELD State of Research and Regulatory Approval by Indication Conceptual Preclinical Anecdotal Pilot Trials Pivotal Trials Outside US Approvals FDA Approvals US Reimbursement Development stage: Cardiovascular Musculoskeletal Hypertension 2016 Bone metastases 2016 Peripheral artery disease 2016 Arthritis - facetogenic 2007 Atrial fibrillation 2016 Desmoid tumors 2017